• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Lifetime management considerations to optimise transcatheter aortic valve implantation: a practical guide.优化经导管主动脉瓣植入术的终生管理考量:实用指南。
EuroIntervention. 2024 Dec 16;20(24):e1493-e1504. doi: 10.4244/EIJ-D-24-00332.
2
Impact of Calcified Raphe on TAVR in Bicuspid Patients: Predicting Redo-TAVR Feasibility and Virtual Planning Implications.钙化中隔对二叶式患者经导管主动脉瓣置换术的影响:预测再次经导管主动脉瓣置换术的可行性及虚拟规划的意义
Circ Cardiovasc Interv. 2025 Jun;18(6):e014802. doi: 10.1161/CIRCINTERVENTIONS.124.014802. Epub 2025 Apr 22.
3
SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial.经导管主动脉瓣植入术使用SAPIEN 3与Myval经导管心脏瓣膜对比研究(COMPARE-TAVI 1):一项多中心、随机、非劣效性试验
Lancet. 2025 Apr 19;405(10487):1362-1372. doi: 10.1016/S0140-6736(25)00106-0. Epub 2025 Apr 2.
4
Valve in valve transcatheter aortic valve implantation (ViV-TAVI) versus redo-Surgical aortic valve replacement (redo-SAVR): A systematic review and meta-analysis.经导管主动脉瓣置入术(ViV-TAVI)中的瓣中瓣技术与再次外科主动脉瓣置换术(redo-SAVR):一项系统评价和荟萃分析
J Interv Cardiol. 2018 Oct;31(5):661-671. doi: 10.1111/joic.12520. Epub 2018 May 20.
5
REdo transcatheter aortic VALVE implantation for the management of transcatheter aortic valve failure: Design and rationale of the REVALVE study.经导管主动脉瓣再次植入治疗经导管主动脉瓣功能障碍:REVALVE研究的设计与原理
Int J Cardiol. 2025 Sep 15;435:133400. doi: 10.1016/j.ijcard.2025.133400. Epub 2025 May 18.
6
Study protocol for an internahaational prospective non-randomised trial evaluating the long-term outcomes of transcatheter aortic valve implantation versus surgical aortic valve replacement for aortic-valve stenosis in patients at risk to severe valve obstruction: the TAVISAR trial.一项国际前瞻性非随机试验的研究方案,该试验旨在评估经导管主动脉瓣植入术与外科主动脉瓣置换术治疗有严重瓣膜狭窄风险的主动脉瓣狭窄患者的长期疗效:TAVISAR试验
BMJ Open. 2025 May 24;15(5):e101417. doi: 10.1136/bmjopen-2025-101417.
7
Transcatheter aortic valve implantation with SAPIEN 3 versus surgical aortic valve replacement in patients with symptomatic severe aortic stenosis at low risk of surgical mortality: a cost-utility analysis for Switzerland.经导管主动脉瓣植入术(SAPIEN 3)与外科主动脉瓣置换术治疗低外科死亡率手术风险的有症状重度主动脉瓣狭窄患者:瑞士的成本-效用分析。
Swiss Med Wkly. 2024 Oct 24;154:3558. doi: 10.57187/s.3558.
8
Health Related Quality of Life (HRQoL) after transcatheter aortic valve implantation in aortic stenosis patients: exploring a novel threshold for clinically significant improvement after 12 months.主动脉瓣狭窄患者经导管主动脉瓣植入术后的健康相关生活质量(HRQoL):探索12个月后具有临床显著改善的新阈值。
J Patient Rep Outcomes. 2025 May 26;9(1):58. doi: 10.1186/s41687-025-00894-1.
9
Valve in valve transcatheter versus redo surgical replacement of a failing surgical bioprosthetic aortic valve: An updated systematic review and meta-analysis.经导管瓣中瓣与再次手术置换失效的外科生物人工主动脉瓣:一项更新的系统评价和荟萃分析
J Cardiol. 2025 Jul 4. doi: 10.1016/j.jjcc.2025.06.022.
10
Feasibility of redo-TAVI in the self-expanding ACURATE neo2 valve: a computed tomography study.自膨式 ACURATE neo2 瓣膜再次经导管主动脉瓣置换术的可行性:一项 CT 研究。
EuroIntervention. 2024 Nov 18;20(22):1405-1415. doi: 10.4244/EIJ-D-24-00367.

引用本文的文献

1
[The TAVI heart team].[经导管主动脉瓣植入术心脏团队]
Herz. 2025 Sep 9. doi: 10.1007/s00059-025-05331-z.
2
Transcatheter Aortic Valve Implantation in Patients with Previous Mitral Valve Surgery-Review.曾接受二尖瓣手术患者的经导管主动脉瓣植入术——综述
J Clin Med. 2025 Jan 23;14(3):735. doi: 10.3390/jcm14030735.

本文引用的文献

1
Transcatheter Aortic Valve Replacement in Patients at High Risk of Coronary Obstruction.冠状动脉阻塞高危患者的经导管主动脉瓣置换术
J Soc Cardiovasc Angiogr Interv. 2022 Jun 22;1(4):100347. doi: 10.1016/j.jscai.2022.100347. eCollection 2022 Jul-Aug.
2
Transcatheter or Surgical Treatment of Aortic-Valve Stenosis.经导管主动脉瓣置换术或主动脉瓣狭窄的外科治疗。
N Engl J Med. 2024 May 2;390(17):1572-1583. doi: 10.1056/NEJMoa2400685. Epub 2024 Apr 8.
3
Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus.自膨式或球囊扩张式 TAVR 在小主动脉瓣环患者中的应用。
N Engl J Med. 2024 Jun 6;390(21):1959-1971. doi: 10.1056/NEJMoa2312573. Epub 2024 Apr 7.
4
Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial.经导管主动脉瓣植入术或外科主动脉瓣置换术:NOTION 试验的 10 年结果。
Eur Heart J. 2024 Apr 1;45(13):1116-1124. doi: 10.1093/eurheartj/ehae043.
5
Feasibility of Redo-Transcatheter Aortic Valve Replacement in Sapien Valves Based on In Vivo Computed Tomography Assessment.基于体内计算机断层扫描评估的经导管主动脉瓣置换术在 Sapien 瓣膜中的可行性。
Circ Cardiovasc Interv. 2023 Nov;16(11):e013497. doi: 10.1161/CIRCINTERVENTIONS.123.013497. Epub 2023 Nov 21.
6
4-Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial.Evolut低风险试验中主动脉瓣狭窄患者的4年结局
J Am Coll Cardiol. 2023 Nov 28;82(22):2163-2165. doi: 10.1016/j.jacc.2023.09.813. Epub 2023 Oct 24.
7
Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years.经导管主动脉瓣置换术在五年内的低危患者中的应用。
N Engl J Med. 2023 Nov 23;389(21):1949-1960. doi: 10.1056/NEJMoa2307447. Epub 2023 Oct 24.
8
Clinical value of CT-derived simulations of transcatheter-aortic-valve-implantation in challenging anatomies the PRECISE-TAVI trial.经导管主动脉瓣植入术在复杂解剖结构中的 CT 模拟的临床价值——PRECISE-TAVI 试验。
Catheter Cardiovasc Interv. 2023 Nov;102(6):1140-1148. doi: 10.1002/ccd.30816. Epub 2023 Sep 5.
9
Long-term outcomes of measured and predicted prosthesis-patient mismatch following transcatheter aortic valve replacement.经导管主动脉瓣置换术后测量和预测的人工假体-患者不匹配的长期结果。
EuroIntervention. 2023 Nov 17;19(9):746-756. doi: 10.4244/EIJ-D-23-00456.
10
Impact of Paravalvular Leak on Outcomes After Transcatheter Aortic Valve Implantation: Meta-Analysis of Kaplan-Meier-derived Individual Patient Data.瓣周漏对经导管主动脉瓣植入术后结局的影响:基于Kaplan-Meier法的个体患者数据的荟萃分析
Struct Heart. 2022 Nov 14;7(2):100118. doi: 10.1016/j.shj.2022.100118. eCollection 2023 Mar.

优化经导管主动脉瓣植入术的终生管理考量:实用指南。

Lifetime management considerations to optimise transcatheter aortic valve implantation: a practical guide.

作者信息

Rao Karan, Baer Alexandra, Bapat Vinayak N, Piazza Nicolo, Hansen Peter, Prendergast Bernard, Bhindi Ravinay

机构信息

Royal North Shore Hospital, Sydney, Australia.

University of Sydney, Sydney, Australia.

出版信息

EuroIntervention. 2024 Dec 16;20(24):e1493-e1504. doi: 10.4244/EIJ-D-24-00332.

DOI:10.4244/EIJ-D-24-00332
PMID:39676551
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11626398/
Abstract

Transcatheter aortic valve implantation (TAVI) is a safe and effective procedure for the treatment of aortic stenosis. With the recently broadened indications, there is a larger cohort of patients likely to outlive their first transcatheter heart valve (THV). This review discusses relevant lifetime planning considerations, focusing on the utility of preprocedural computed tomography imaging to help implanters future-proof their patients who are likely to outlive their first valve. The initial priority is to optimise the index procedure by maximising THV haemodynamic function and durability. This involves maximising the effective orifice area, minimising the risk of new pacemaker implantation, reducing paravalvular regurgitation, and preventing coronary obstruction and annular rupture. In patients requiring a second valve procedure, a significant proportion will require a TAVI-in-TAVI, and implanters should consider the key priorities for a redo procedure, including the increased risks of patient-prosthesis mismatch and conduction abnormalities, promoting coronary reaccessibility, and preventing coronary obstruction and sinus sequestration. Careful planning can identify potential hurdles as well as predict the feasibility and likely outcomes of redo-TAVI, to help individualise care over the lifetime of each patient.

摘要

经导管主动脉瓣植入术(TAVI)是治疗主动脉瓣狭窄的一种安全有效的方法。随着适应症最近的扩大,有更多患者可能在其首个经导管心脏瓣膜(THV)植入后存活更长时间。本综述讨论了相关的终身规划考量因素,重点关注术前计算机断层扫描成像的作用,以帮助植入者为可能在首个瓣膜植入后存活更长时间的患者做好未来的准备。首要任务是通过最大化THV的血流动力学功能和耐久性来优化首次手术。这包括最大化有效瓣口面积、最小化新植入起搏器的风险、减少瓣周反流、预防冠状动脉阻塞和瓣环破裂。在需要进行二次瓣膜手术的患者中,很大一部分将需要进行TAVI-in-TAVI,植入者应考虑再次手术的关键优先事项,包括患者-假体不匹配和传导异常风险增加、促进冠状动脉可及性以及预防冠状动脉阻塞和窦隔离。精心规划可以识别潜在障碍,并预测再次TAVI的可行性和可能结果,以帮助为每位患者的一生提供个性化护理。